Company · 21.20 · Manufacture of pharmaceutical products
SIA SILVANOLS
From the company website
We combine our knowledge of the medicinal properties of plants with the latest technological advances to meet people’s needs
Apvienojam zināšanas par augu ārstnieciskajām īpašībām ar jaunākajām tehnoloģiju iespējām, lai apmierinātu cilvēku vajadzības
Turnover · 2025
5.5 M €
+3% vs previous year
Employees
53
Turnover per employee: 103 k €
Taxes paid · 2024
1.1 M €
Payroll fund / employees: 21 k €
Payroll fund · 2024 estimate
1.1 M €
Wage estimate, gross: 1,687 €
Tax breakdown · 2026 Q3
Money paid to and returned by the tax office during the quarter, not tax charged. VAT on purchases is already deducted inside the payment — it does not appear here separately. A refund arises only when deductions exceed the VAT charged on sales: for exporters, intra-EU suppliers, and under the domestic reverse charge (construction, timber, scrap metal), not for every company with large purchases. Compare with the turnover of the same quarter, not of the year.
Quarterly history
| Quarter | Total paid to VID | Personal income tax | Social contributions | VAT paid · after deductions | VAT refunded by the state |
|---|---|---|---|---|---|
| 2026 Q3 | 236 k € | 36 k € | 84 k € | 112 k € | 0 € |
| 2026 Q2 | 273 k € | 33 k € | 80 k € | 141 k € | 0 € |
| 2026 Q1 | 212 k € | 33 k € | 80 k € | 110 k € | 12 k € |
| 2025 Q4 | 406 k € | 43 k € | 80 k € | 283 k € | 0 € |
| 2024 | 1.1 M € | 190 k € | 373 k € | — | — |
| 2023 | 622 k € | 184 k € | 377 k € | — | — |
| 2022 | 531 k € | 160 k € | 349 k € | — | — |
Financial health · From the 2025 balance sheet
Cross-section against the peer median
Compared with companies under NACE code 21.20 — 19.
What changed
Position among peers
Indicators
panel.caveats
Building coordinate from the State Address Register. Figures come from public registers. Wage, export share and address confidence are estimates and are always labelled as such.
Similar companies
Rivals in the niche
Filed annual reports
Figures the company filed itself. Bar length shows size within the column; the longest is its best year. An empty cell means no report for that year — not a zero.
| Year | Turnover | Net profit | Assets | Employees |
|---|---|---|---|---|
| 2025 | 5.5 M € | 701 k € | 3.9 M € | 53 |
| 2024 | 5.3 M € | 178 k € | 3.5 M € | 52 |
| 2023 | 5.6 M € | 363 k € | 3.4 M € | 51 |
| 2022 | 5.1 M € | 306 k € | 2.9 M € | 54 |
| 2021 | 3.2 M € | 175 k € | 2.9 M € | 53 |
| 2020 | 3.7 M € | -250861 € | 2.8 M € | 60 |
Source: annual reports from the Register of Enterprises, as filed. A missing year is a missing report, not a loss.
Foreign trade of the industry · 2025
All companies in division 21 — Manufacture of pharmaceutical products — not this company. Trade by individual firms is not published by law; by industry it is.
Industry goods exports
261.1 M €
Industry goods imports
50.1 M €
Exported most: Chemical products — 256.9 M €, Prepared foodstuffs, beverages, tobacco — 3.9 M €, Textiles and textile articles — 216 k €
Source: Official Statistics of Latvia, table ATN011, goods trade by the activity of the trading enterprise. “Not published” means the figure would identify a single firm — it is not a zero.
State support received
Sources: EU fund project registers kept by the Central Finance and Contracting Agency and the de minimis register of the Ministry of Finance, both CC0. Amounts are as published. Support granted to natural persons is not shown.
Open tenders for this company's profile